Corrigendum: CDKN2A determines mesothelioma cell fate to EZH2 inhibition

Front Oncol. 2022 Nov 23:12:1081632. doi: 10.3389/fonc.2022.1081632. eCollection 2022.

¹ Department of Pharmaceutical Sciences, University of Piemonte Orientale (UPO), Novara, Italy.
² School of Life and Health Sciences, Aston University, Birmingham, United Kingdom.
³ Laboratory of Cellular Biochemistry and Molecular Biology, Centro di Ricerca in Biochimica E Nutrizione dello Sport (CRIBENS), Catholic University of the Sacred Heart, Milan, Italy.
⁴ Department of Health Science, University of Piemonte Orientale (UPO), Novara, Italy.
⁵ Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom.

Abstract

[This corrects the article DOI: 10.3389/fonc.2021.678447.].

Keywords: CDKN2A/p16ink4a; EZH2 inhibitor; TG2; malignant pleural mesothelioma; multicellular spheroids.